Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Lintlha tse Ncha mabapi le Therapy ea Solid Tumors

ngotsoeng ke mohlophisi

Kajeno Oncolytics Biotech® Inc. e phatlalalitse phatlalatso ea data ea preclinical e bonts'ang ts'ebetso ea synergistic e khahlanong le mofets'e ea pelareorep e kopantsoeng le kalafo ea lisele tsa chimeric antigen receptor (CAR) T ka lihlahala tse tiileng. Pampiri ena, e nang le sehlooho se reng "Katoloso e amanang le kokoana-hloko ea Oncolytic ea lisele tse peli tse khethehileng tsa CAR T e ntlafatsa katleho khahlanong le lihlahala tse tiileng ho litoeba," e ile ea hatisoa ho Science Translational Medicine ka tšebelisano le bafuputsi ba litsi tse 'maloa tse tummeng, ho akarelletsa le Mayo Clinic le Duke University. Sehokelo sa pampiri se ka fumanoa ka ho tobetsa mona.

Thomas Heineman, MD, Ph.D., Ofisiri e ka Sehloohong ea Bongaka ea Oncolytics Biotech Inc. "Le hoja lisele tsa CAR T li hlahisitse nako e telele, "Ho ba le liphetho tsena tse hatisitsoeng koranteng e joalo ea liphello tse phahameng ho fana ka bopaki ba bohlokoa ba ka ntle ba bohlokoa ba bona. Kalafo ea malignancies1, the immunosuppressive tumor microenvironments (TMEs) ea mofets'e o tiileng oa setho ho fihlela joale e fokolitse matla a bona a ho sebetsa matšoaong ana. Pelareorep e 'nile ea bontšoa ka makhetlo hore e fetola li-TME tsa immunosuppressive,' me khatisong ea hona joale pelareorep e bontšoa ho thusa ho sebetsa hantle ha lisele tsa CAR T mefuteng e mengata ea murine e tiileng ea tumor. Ena ke phumano e matla ea hore, haeba e fetoleloa tleliniking, e ka ntlafatsa haholo boemo ba bakuli ba nang le mefuta e mengata ea mofets'e e atileng haholo ka ho fana ka khetho e ncha le e ka tšoarellang nako e telele. Ka ho bonts'a bokhoni ba ho ntlafatsa mamello ea T cell, ho fokotsa ho phonyoha ha li-antigen, le ho hlola li-TME tsa tumor tse thata, ho kenyelletsoa ha pelareorep ho sebetsana le litšitiso tse tharo tse thata ka ho fetisisa tsa kalafo ea CAR T.

Andrew de Guttadauro, Mopresidente oa Oncolytics Biotech US le Hlooho ea Lefatše la Ntšetso-pele ea Khoebo, o ekelitse, "Le ha ho bile le phetoho e kholo kalafong ea mafu a mang a mofets'e le ho feta lidolara tse limilione tse likete tse rekisoang selemong se fetileng, kalafo ea CAR T hajoale e thusa feela karoloana e nyane ea bakuli ba tšoeroeng ke lefu la mali. mafu a kotsi. Ka liphetho tsena tsa morao-rao, joale re na le bopaki bo matla ba hore pelareorep e ka notlolla boleng ba liphekolo tsa CAR T ka ho holisa bokhoni ba bona ba khoebo 'marakeng o moholo oa bakuli ba mofets'e ba loanang le lihlahala tse tiileng. "

Liphuputso tsa preclinical tse hatisitsoeng pampiring li ile tsa hlahloba ho phehella le ho sebetsa ha lisele tsa CAR T tse jereng pelareorep ("CAR / Pela therapy") ka mefuta e mengata ea li-tumor tse tiileng tsa murine. Liphello tsa ho kopanya phekolo ea CAR / Pela le tekanyo e latelang ea intravenous ea pelareorep ("pelareorep boost") le eona e ile ea fuputsoa. Lintlha tsa bohlokoa le liqeto tse tsoang pampiring li kenyelletsa:

• Ts'ebetso ea ho phehella le e khahlanong le mofets'e ea lisele tsa CAR T e ile ea ntlafala haholo ha e kentsoe pelareorep. Ha ho bapisoa le phekolo e le 'ngoe feela, phekolo ea CAR/Pela e ile ea lebisa melemo ea lipalo-palo ea ho pholoha letlalong la murine le mefuta ea kankere ea boko.

• Phekolo ea CAR / Pela e lateloa ke pelareorep boost e lebisitseng katlehong e ntlafetseng ea letlalo la murine le mefuta ea kankere ea boko le phekolo ea tumor ho> 80% ea litoeba tse tšoaroang ka mokhoa o mong le o mong.

• Ho kenya lisele tsa CAR T ka pelareoep ho lebisitse ho ntlafatso ea lisele tsa kankere le ho thibela antigen ho phonyoha ka vivo ka ho hlahisa lisele tsa CAR T tse nang le likarolo tse peli tse tobang li-antigen tsa tsona tse entsoeng le antigen ea T cell receptor. Liphetho tsena li bontša hore phekolo ea CAR/Pela e ka fana ka melemo ea phekolo ea nako e telele ha e bapisoa le phekolo ea lisele tsa CAR T feela.

Dr. Matt Coffey, Mopresidente le Ofisiri e ka Sehloohong ea Oncolytics Biotech Inc. le sengoli-'moho le pampiri ba re, "Liphetho tsena tse monate ke mohlala o babatsehang oa kamoo re matlafatsang tšebelisano 'moho le baetapele ba bohlokoa ba maikutlo le litsi tsa pele tsa lipatlisiso ho atolosa bokhoni ba pelareorep. phello ea phekolo. Sena se re nolofalletsa ho lula re tsepamisitse maikutlo lenaneong la rona la mofetše oa matsoele, le bonts'itseng kamoo bokhoni ba pelareorep ba ho khothaletsa ho kenella ha lisele tsa tumor T bo lebisang ho synergy le li-checkpoint inhibitors tleliniking. Liphuputso tsena tse sa tsoa hatisoa tsa pele li bonts'a melemo ea synergistic ea pelareorep e atoloha le ho feta li-inhibitors tsa tlhahlobo mme e totobatsa monyetla oa ho eketsa palo ea bakuli ba rona ba khonang ho rarolla mathata. Ha re ntse re hahamalla monyetla ona ho ea pele, re ikemiselitse ho sebelisa likamano le balekane ba thuto kapa indasteri e le hore re ka tsoela pele ho phethahatsa merero ea rona ea bongaka le ea khoebo ka katleho. ”

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...